New York, June 12, 2026, 11:28 a.m. ET
- POET Technologies shares rose about 13% in late-morning Nasdaq trading, despite fresh securities-class-action deadline reminders.
- The next major catalyst is the June 26 shareholder meeting, where investors will watch the company’s U.S. redomiciling plan and any update on commercial execution.
- The stock remains a high-risk AI infrastructure play: POET has a large funding runway and order pipeline, but revenue is still tiny and legal, dilution and execution risks are elevated.
POET Technologies Inc. stock climbed sharply Friday, trading at $12.735, up $1.485, or about 13.2%, from the prior close, with volume above 17 million shares and an intraday range of $11.00 to $12.79. The move matters because POET has become a highly volatile Nasdaq-listed AI photonics name: buyers are betting that its optical-engine technology can move from development-stage promise to commercial scale, while sellers remain focused on lawsuits, order risk and dilution.
The latest news flow around POET has centered on securities-class-action reminders rather than a new operating announcement. Pomerantz said Thursday that a class action had been filed against POET and that investors who bought during the class period have until June 29 to seek appointment as lead plaintiff, the investor selected to represent other shareholders in the case. Rosen Law Firm’s June 11 notice said the case covers purchases between April 1 and 8:57 a.m. ET on April 27 and includes allegations over POET’s PFIC status and disclosures around business relationships; those allegations have not been proven, and Rosen’s notice also said no class has been certified.
The legal overhang traces back to POET’s April 27 purchase-order update. The company said Marvell Semiconductor, which had acquired Celestial AI, canceled all purchase orders from Celestial AI after citing alleged confidentiality violations tied to purchase-order and shipping information. That disclosure was a major stock-price event because orders are especially important for development-stage companies: when a future revenue stream is canceled, investors often mark down the stock to reflect lower expected sales and higher business risk. POET said at the time it remained focused on other customer deliveries, including a separate purchase order valued at about $5 million.
The bull case is that POET has since secured enough capital to keep pursuing scale. On May 18, the company said it closed a $400 million registered direct offering to a single institutional investor, issuing about 19.05 million common shares plus a warrant for the same number of shares. The company said the proceeds would support manufacturing expansion, research and development, acquisitions, light-source products and working capital. Chief Executive Dr. Suresh Venkatesan said POET was “expanding our capacity by roughly ten-fold,” a signal that management is positioning the company for higher-volume production rather than small engineering programs. POET Technologies
The commercial centerpiece is POET’s Lumilens agreement. POET said Lumilens placed an initial $50 million purchase order for EOI-based optical engines, with the broader relationship potentially scaling to more than $500 million in cumulative purchases over five years. EOI, or Electrical-Optical Interposer, refers to a platform intended to combine electrical and optical functions at wafer level, which POET says could help address bandwidth bottlenecks in AI data centers. The important caveat is that POET also said fulfillment and related revenue depend on successful development, module qualification and manufacturing scale-up; engineering samples are expected in late 2026, with production ramp aligned to 2027 deployments.
The bear case is that the valuation still rests heavily on future execution. In the first quarter, POET reported non-recurring engineering and product revenue of just $503,389 and a net loss of $12.3 million, or 8 cents per share. Non-recurring engineering, or NRE, means project-specific engineering work rather than steady, repeat product sales. That gap between today’s revenue base and the stock’s AI-infrastructure expectations leaves the shares sensitive to any delay, failed qualification, customer cancellation or financing concern. The May financing also came with warrants, which are rights to buy shares later at a fixed price; if exercised, they can bring in cash but also create dilution, meaning existing holders own a smaller percentage of the company.
The next major catalyst is POET’s June 26 virtual annual meeting, with the redomiciling plan in focus. POET has said it may be treated as a PFIC, a Passive Foreign Investment Company, for 2025; PFIC status can create adverse U.S. tax consequences for American shareholders unless mitigating elections are made. The company has said its board approved redomiciling in the U.S. to eliminate the possibility of future PFIC classification, while also warning there is no assurance the move will be completed. The June 29 lead-plaintiff deadline then follows as a second near-term legal milestone.
On verified facts, POET looks risky today rather than clearly attractive or fairly valued. Stocks rise when investors decide a company’s future profits or strategic value are worth more, and they fall when lawsuits, dilution, lost orders or execution doubts make that future less certain. Friday’s rally shows traders are still willing to pay for POET’s AI photonics upside, but the company must convert the Lumilens program and other customer work into qualified products, repeat revenue and credible manufacturing scale before the stock can be judged on fundamentals rather than expectation.
